Cargando…

A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety

INTRODUCTION: The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-García, Francisco, Ruano, Juan, Gay-Mimbrera, Jesús, Aguilar-Luque, Macarena, Sanz-Cabanillas, Juan L., Hernández Romero, José L., Garcia-Nieto, Antonio Velez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002324/
https://www.ncbi.nlm.nih.gov/pubmed/29626322
http://dx.doi.org/10.1007/s13555-018-0235-4
_version_ 1783332176658432000
author Gómez-García, Francisco
Ruano, Juan
Gay-Mimbrera, Jesús
Aguilar-Luque, Macarena
Sanz-Cabanillas, Juan L.
Hernández Romero, José L.
Garcia-Nieto, Antonio Velez
author_facet Gómez-García, Francisco
Ruano, Juan
Gay-Mimbrera, Jesús
Aguilar-Luque, Macarena
Sanz-Cabanillas, Juan L.
Hernández Romero, José L.
Garcia-Nieto, Antonio Velez
author_sort Gómez-García, Francisco
collection PubMed
description INTRODUCTION: The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat these pathologies, and although they are becoming more selective, they are not exempt from adverse events and high costs. Integrating the best research evidence with clinical experience and patient needs has been shown to improve care, health, and cost outcomes. This is because evidence-based guidelines rank interventions according to cost-effectiveness. However, evidence on this topic is scarce for several reasons. First, although randomized clinical trials currently provide the best evidence, they are not always available. Second, there are no secondary scientific studies that summarize the use of IL-1-targeting agents in dermatology. We therefore sought to develop an a priori protocol for broadly reviewing the available evidence on the use of IL-1-targeting drugs in the treatment of dermatological diseases. METHODS: We used the latest methodology to perform a scoping review as described in the Joanna Briggs Institute manual. RESULTS/DISCUSSION: Developing and applying a methodology for evidence synthesis promotes reproducibility and increases the validity of secondary scientific investigations, making it the optimal strategy for scientifically synthesizing a broad field such as the indications for and the mechanisms of action, efficacies, safety, and costs of IL-1-targeting drugs in the treatment of dermatological diseases. Quantitative synthesis facilitates the detection of knowledge gaps and the identification of new questions that can be addressed through systematic reviews. We present an a priori protocol for exploring the available evidence on this topic.
format Online
Article
Text
id pubmed-6002324
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-60023242018-06-29 A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety Gómez-García, Francisco Ruano, Juan Gay-Mimbrera, Jesús Aguilar-Luque, Macarena Sanz-Cabanillas, Juan L. Hernández Romero, José L. Garcia-Nieto, Antonio Velez Dermatol Ther (Heidelb) Review INTRODUCTION: The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat these pathologies, and although they are becoming more selective, they are not exempt from adverse events and high costs. Integrating the best research evidence with clinical experience and patient needs has been shown to improve care, health, and cost outcomes. This is because evidence-based guidelines rank interventions according to cost-effectiveness. However, evidence on this topic is scarce for several reasons. First, although randomized clinical trials currently provide the best evidence, they are not always available. Second, there are no secondary scientific studies that summarize the use of IL-1-targeting agents in dermatology. We therefore sought to develop an a priori protocol for broadly reviewing the available evidence on the use of IL-1-targeting drugs in the treatment of dermatological diseases. METHODS: We used the latest methodology to perform a scoping review as described in the Joanna Briggs Institute manual. RESULTS/DISCUSSION: Developing and applying a methodology for evidence synthesis promotes reproducibility and increases the validity of secondary scientific investigations, making it the optimal strategy for scientifically synthesizing a broad field such as the indications for and the mechanisms of action, efficacies, safety, and costs of IL-1-targeting drugs in the treatment of dermatological diseases. Quantitative synthesis facilitates the detection of knowledge gaps and the identification of new questions that can be addressed through systematic reviews. We present an a priori protocol for exploring the available evidence on this topic. Springer Healthcare 2018-04-06 /pmc/articles/PMC6002324/ /pubmed/29626322 http://dx.doi.org/10.1007/s13555-018-0235-4 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Gómez-García, Francisco
Ruano, Juan
Gay-Mimbrera, Jesús
Aguilar-Luque, Macarena
Sanz-Cabanillas, Juan L.
Hernández Romero, José L.
Garcia-Nieto, Antonio Velez
A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety
title A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety
title_full A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety
title_fullStr A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety
title_full_unstemmed A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety
title_short A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety
title_sort scoping review protocol to explore the use of interleukin-1-targeting drugs for the treatment of dermatological diseases: indications, mechanism of action, efficacy, and safety
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002324/
https://www.ncbi.nlm.nih.gov/pubmed/29626322
http://dx.doi.org/10.1007/s13555-018-0235-4
work_keys_str_mv AT gomezgarciafrancisco ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT ruanojuan ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT gaymimbrerajesus ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT aguilarluquemacarena ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT sanzcabanillasjuanl ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT hernandezromerojosel ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT garcianietoantoniovelez ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT gomezgarciafrancisco scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT ruanojuan scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT gaymimbrerajesus scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT aguilarluquemacarena scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT sanzcabanillasjuanl scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT hernandezromerojosel scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety
AT garcianietoantoniovelez scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety